The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

被引:5
|
作者
Li, Xiaoyan [1 ]
He, Jie [2 ,3 ]
Sun, Qiuhua [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Nursing, 548 Binwen Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Chengdu 610500, Sichuan, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Sichuan, Peoples R China
关键词
Sarcopenia; Metabolic dysfunction-associated steatotic; liver disease (MASLD); Prevalence; Systematic review; Meta-analysis; INSULIN-RESISTANCE; FIBROSIS; NAFLD; RISK; STEATOHEPATITIS; QUALITY;
D O I
10.1016/j.clnu.2024.07.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and aims: Sarcopenia is a common complication in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). However, the prevalence and its impact on the survival of sarcopenia in patients with MASLD is unknown. In this study, we aimed to assess the prevalence and effects of sarcopenia in patients with MASLD. Methods: Systematic review and meta-analysis of full texts of relevant studies were searched from inception until June 12, 2024 in five databases (PubMed, Cochrane Library, Embase, Web of Science, and the China National Knowledge Infrastructure). Next, we assessed the prevalence of sarcopenia in MASLD, and calculated the ORs and HRs between sarcopenia and MASLD based on the adjusted data from individual studies. Statistical analyses were performed using Stata 11.0. Results: Of the 2984 records considered, 29 studies recruiting 63,330 patients were included. The pooled prevalence of sarcopenia in patients with MASLD was 23.5% overall (95% CI; 19.1%-27.9%, I2 = 99.6%), and was higher in Asian patients, male, cross-sectional studies, when BIA were employed to measure muscle mass, one criterion of diagnosis sarcopenia, MASLD was diagnosed employing MRI, and moderate-quality studies. Sarcopenia was associated with MASLD patients (adjusted odds ratio [aOR] 2.08, 95% CI 1.58 -2.74, I2 = 93.6%) with similar findings in subgroups stratified by age, study design, methods for measuring muscle mass, assessment method to detect sarcopenia, and study quality. The association between all-cause mortality further supports the association between sarcopenia and poor prognosis with MASLD (aHR 1.59, 95% CI 1.33-1.91, I2 = 0%). Conclusions: Sarcopenia was strongly associated with MASLD progression and was a risk factor not only for MASLD pathogenesis but was also markedly correlated with MASLD-associated mortality. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2005 / 2016
页数:12
相关论文
共 50 条
  • [1] Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Malik, Adnan
    Javaid, Sadia
    Malik, Muhammad Imran
    Qureshi, Shahbaz
    ANNALS OF HEPATOLOGY, 2024, 29 (06)
  • [2] Electrocardiographic abnormalities in patients with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis
    Dimala, Christian Akem
    Nso, Nso
    Wasserlauf, Jeremiah
    Njei, Basile
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (07)
  • [3] The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis
    Lv, Qiong
    Zhao, Huashan
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [4] Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis
    Jamil, Asma
    Chivese, Tawanda
    Elshaikh, Usra
    Sendall, Marguerite
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [5] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025, : 94 - 103
  • [6] Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Singh, Avneet
    Buckholz, Adam
    Kumar, Sonal
    Newberry, Carolyn
    NUTRIENTS, 2024, 16 (05)
  • [7] Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
    Malik, Adnan
    Malik, Muhammad
    Qureshi, Shahbaz
    CANADIAN LIVER JOURNAL, 2024, 7 (01): : 40 - 53
  • [8] Prognostic value of liver stiffness in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
    Mu, Yijun
    Peng, Cheng
    Chang, Huijun
    Wang, Shaotong
    Zuo, Xiuli
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (08) : 416 - 422
  • [9] Sarcopenia and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
    Abenavoli, Ludovico
    Statsenko, Michael
    Scarlata, Giuseppe Guido Maria
    Morano, Domenico
    Myazin, Roman
    Emelyanov, Dmitriy
    LIVERS, 2024, 4 (04): : 495 - 506
  • [10] Disparities for Hispanic Adults With Metabolic Dysfunction-associated Steatotic Liver Disease in the United States: A Systematic Review and Meta-analysis
    Tesfai, Kaleb
    Pace, Jordan
    El-Newihi, Nora
    Martinez, Maria Elena
    Tincopa, Monica A.
    Loomba, Rohit
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2025, 23 (02) : 236 - 249